Active Surveillance of Prostate Cancer

Article

Prostate cancer is the most common serious cancer in men and the second most common cause of death from cancer.

Prostate cancer is the most common serious cancer in men and the second most common cause of death from cancer. One in six men will be diagnosed with it during their lifetime resulting in about 200,000 new cases during the next 12 months. Despite the number of men affected, the prevention, diagnosis, and treatment of this disease probably are more controversial than any other cancer. Prostate Cancer: Reducing Your Risks explains both sides of the various controversies in an easy to understand manner. It provides you with balanced, unbiased information based on the best scientific studies available. Equipped with this information, you will be able to decide the best course of action to maximize your survival and your quality of life.

Related Videos
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
The JAK Inhibitor Safety Conversation
Jonathan Silverberg, MD, PhD, MPH | Credit: George Washington University
Secukinumab and Bimekizumab for Hidradenitis Suppurativa
Kaitlin Mayne, MBChB | Credit X.com
Mona Shahriari, MD | Credit Central Connecticut Dermatology
Cindy X. Cai, MD: Impact of Race, Neighborhood on Diabetic Retinopathy Care | Image Credit: Johns Hopkins University
Awaiting FDA Decision on MDMA Assisted Therapy, with Bessel van der Kolk, MD
Bessel van der Kolk, MD: The Future of MDMA Assisted Therapy in PTSD
© 2024 MJH Life Sciences

All rights reserved.